Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study - Subbiah, V; Hu, M I; Wirth, L J (Lancet Diabetes Endocrinol, 2021)
et al.